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Abstract
Bladder cancer (BC) is an increasingly frequent cancer worldwide, being  
currently the sixth most frequent tumor and the thirteenth leading cause of cancer 
death. Among all BC cases, pathologists have identified several histomorphologies 
different from the conventional urothelial carcinoma. Although rare, these histologic 
variants have a distinct growth pattern, an altered cell differentiation and an unusual 
clinical behavior, especially concerning clinical presentation at diagnosis, response 
to the standard treatment and prognosis. Therefore, an updated review of this topic 
should be useful to aid clinicians in a better evidence-based decision-making. This 
chapter aims to summarize the current literature on the most common histologic 
variants regarding their epidemiology, clinical presentation at diagnosis, treatment 
options and prognosis. This includes both non-muscle invasive BC and muscle 
invasive BC as well as metastatic disease. A special focus will be placed on the role of 
neoadjuvant chemotherapy and early cystectomy and its prognostic implications.
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1. Introduction
Bladder cancer is an entity characterized by a wide range of different histomor-
phologies as well as distinct clinical courses. Approximately 75% of tumors are 
classified as pure urothelial carcinoma (transitional cell carcinoma), the remaining 
25% consist of other histological variants. Several histological variants have been 
identified throughout the years, based on morphological features [1]. During the 
past decade, there is a trend of increasing evidence of the clinical relevance of his-
tological variants, some them with data showing adverse pathological features and 
poor prognosis [2]. The acknowledgment of this information has been changing the 
clinical reasoning and disease management in patients with BC.
Pure non-urothelial bladder cancer comprises only a small minority (about 5%) 
of all bladder cancers. They include squamous cell carcinoma, adenocarcinoma, 
small cell carcinoma, and mixed histology tumors, with squamous and adenocar-
cinoma comprising the most frequent morphologies. Non-urothelial histologic 
subtypes were generally thought to have a worse prognosis compared to urothelial 
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BC [3], however, once corrected for stage and patient-related factors, a significant 
proportion of them may have a similar prognosis.
On other hand, urothelial tumors with a variant histology component are more 
frequent than non-urothelial tumours. The classification of histologic variants is 
mainly based on morphologic features, being each differentiation pattern charac-
terized by a distinct biological behavior, such as propensity for local recurrence and 
metastasis [4]. Non-muscle invasive BC with variant histology most likely remains 
underdiagnosed, as it seems challenging to identify its presence on TURB speci-
mens. Current data suggests that variant histologies confer high-risk status to non-
muscle invasive tumors, despite some studies had demonstrated similar progression 
rates in comparison with pure urothelial carcinomas (UC) associated with high risk 
factors [5]. Therefore, the question arises, does variant histology justify an aggres-
sive treatment approach with early radical cystectomy?
The treatment of BC has evolved throughout the years such that clinical markers 
of risk are now used to guide us through algorithms that incorporate transurethral 
surgery, intravesical chemotherapy and immunotherapy, radical cystectomy, 
systemic combination chemotherapy, and sometimes radiation therapy. Therefore, 
the optimal risk stratification may include variant histology as a relevant factor in 
clinical decision making [6].
This chapter focuses on most common histological variants and discusses  
different treatment options and their prognostic value.
2. Histologic variants of Urothelial Carcinoma
Urothelial carcinoma (UC) is remarkable for displaying a wide range of diversity 
in its morphological appearance, which may reflect its molecular heterogeneity. 
Urothelial tumors with divergent differentiation are the most common histology 
variant within urothelial carcinomas [7]. The term refers to tumors that present 
some degree of typical urothelial carcinoma (invasive or in situ) with other histo-
morphologies such as squamous or glandular differentiation.
Squamous and Glandular differentiation are most common histology variants 
[8, 9]. UCs with squamous or glandular differentiation are distinct entities and 
should be distinguished from both pure squamous cell carcinoma (SCC) and or 
adenocarcinoma (AC) which do not include any urothelial components and subse-
quently present different clinical behavior. Other subtypes of UC variants include 
rarer differentiations including trophoblastic and small cell differentiation.
Urothelial carcinomas with divergent differentiation were previously thought to 
present at a more advanced stage at diagnosis and early reports indicated a poorer 
survival rate. More recently, studies have shown that, if standardized for stage, 
patients with either squamous or glandular UCs have survival rates comparable with 
those with pure UC.
Yet, current guidelines still categorize UC with variant histology in the highest 
risk category in which early radical cystectomy should be considered [8].
2.1 Urothelial carcinomas with squamous differentiation
Urothelial carcinomas with squamous differentiation are found in up to 40% of 
UCs and the inclusion of keratinization and/or intercellular bodies (Figure 1) are 
their main histological hallmarks [7]. The distinction between UC with squamous 
differentiation and pure squamous cell carcinomas (SCC) of the bladder remains a 
challenge for pathologists, especially in transurethral resection (TUR) specimens, 
because both tend to share most of the same immunohistochemical components.
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Among NMIBC cases, UCs with squamous differentiation are frequently associ-
ated with high-grade and high-stage tumors at diagnosis and tend to have a less 
favorable response to intravesical chemotherapy or BCG instillations [10]. In the 
MIBC disease setting, studies have shown that response rate of neoadjuvant chemo-
therapy may be similar to conventional UC [11], although with a poor prognosis [2].
2.2 Urothelial carcinomas with glandular differentiation
Glandular differentiation comprises approximately 10% of all UCs and is char-
acterized by true gland formation (Figure 2), resembling colonic adenocarcinoma, 
signet ring carcinoma or mucinous/colloid carcinoma. It may be associated with UC 
in situ or less frequently with in situ UC with glandular differentiation. Pseudo glan-
dular aspects with mucin expression may be observed in conventional UC and should 
not be confused with either UC with glandular differentiation or bladder adenocar-
cinoma, although the lack of immunohistochemical markers makes the distinction 
challenging [12]. Telomerase reverse transcriptase (TERT) mutations are seen in the 
majority of UCs with glandular differentiation and not in adenocarcinomas of the 
bladder [13]; nevertheless, this marker is yet to be implemented in routine clinical use.
In terms of clinical significance of this differentiation, it tends to present at a 
higher stage, but it is not a predictor of adverse prognosis in stage-matched patients, 
showing similar rates of recurrence-free and overall survival when compared to 
conventional UC [5].
It is important to note that data from studies has showed that intravesical BCG 
treatment might play a key role in patients with UC with glandular differentiation, 
with this therapy presenting reasonable response rates [14, 15].
2.3 Urothelial Carcinomas with Trophoblastic Differentiation
UC with trophoblastic differentiation is a rare entity with only a few cases 
reported, and it is characterized by the expression of the beta subunit of the human 
chorionic gonadotropin (ßhCG) (Figure 3). This subtype must be distinguished from 
Figure 1. 
Squamous differentiation is characterized by the presence of both urothelial carcinoma and keratin clusters and 
intercellular bodies (HE × 100).
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Figure 3. 
The image shows a cluster of syncytiotrophoblastic giant cells enclosed by high-grade urothelial carcinoma 
(HE × 100).
pure choriocarcinoma which requires the demonstration of the isochromosome 12p, 
a hallmark of germ cell tumors. The percentage of ßhCG-immunoreactive cells is 
associated with higher stage and grade of the disease. Elevated secretion of ßhCG into 
the serum may be associated with an observable poorer response to chemotherapy 
and radiation, and it can be used as a marker in the follow-up of these patients [2].
2.4 Urothelial Carcinomas with Small Cell Differentiation
UC can exhibit neuroendocrine differentiation in the form of small cell carci-
noma. These tumors are usually treated similarly to their counterpart in the lungs.
Figure 2. 
Glandular differentiation encompasses gland-like lumina or fully developed adenocarcinoma with intestinal 
morphology (HE × 100).
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2.5 Nested Urothelial Carcinoma
Based on the 2016 WHO classification, the nested variant includes UC with 
small tubules and microcysts (Figure 4). This histologic variant can often 
resemble benign cytology [16]. It is characterized by disorderly proliferation of 
confluent nests, with minimal cell atypia [17], which can often delay the definitive 
diagnosis.
Nested UCs usually present as high stage disease and may be associated with a 
worse prognosis compared with pure nested variants [14]. It shares similar immu-
nohistochemical features and clinical outcomes with the conventional UC, with 
little to no difference in recurrence rate or survival when treated with RC in either 
NMIBC and MIBC [17].
2.6 Microcystic Urothelial Carcinoma
The microcystic UC variant, like the nested UCs, is characterized by a benign 
cytologic resemblance features. It is constituted by oval cysts, lined by urothe-
lial, low columnar or flattened epithelium (Figure 5) and focal conventional UC 
may be present in up to 40% of tumors [18]. Foci of high-grade UC are seen in up 
to 40% of cases, which may help distinguish this variant form benign mimicking 
tumors [14].
Differential diagnosis includes benign proliferations such as florid polypoid 
cystitis cystica and glanduraris and adenocarcinoma [19].
There is very limited information about prognostic implications of microcystic 
histology in BC, only a few case reports and case series have been published. The 
largest study to date (N = 20) reported 55% of patients died at a mean follow-up of 
30 months after radical cystectomy (RC). However, when controlled for stage, there 
was no statistically significant difference in survival compared with patients with 
pure UC [20].
Figure 4. 
The nested variant of urothelial carcinoma consists of small, discrete nests with bland morphology distributed 
irregularly in the lamina propria. The size of nests is much smaller than von Brunn’s nests of normal 
urothelium (HE × 40).
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Figure 6. 
Infiltrating tumors cells with slender filiform processes without fibrovascular cores and multiple small tumor 
nests within a single lacunar space, mostly not enclosing a true fibrovascular core (HE × 200).
2.7 Micropapillary Urothelial Carcinoma
Micropapillary Urothelial Carcinoma (MPUC) is a variant seen most commonly 
in males, being characterized by small tumour nests surrounded by lacunar spaces 
(Figure 6). It is a clinically aggressive variant that usually presents at an advanced 
stage that accounts for 2–5% of UCs [14, 21]. ERBB2 (HER2) amplification by 
FISH is seen more commonly in patients with MPUC versus conventional UC, such 
expression has been related to worse cancer-specific survival although it also pro-
vides a potential role for HER2 targeted therapy [22]. Single institution case-series 
Figure 5. 
Characterized by the formation of microcysts which may mimic cystitis cystica in small specimens. Cytologic 
atypia is minimal or entirely absent (HE × 100).
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have demonstrated poorer outcomes in patients with MPUC than those with pure 
UC [23]. However, more recent studies demonstrated that, when controlled for 
stage, this may not be the case.
Non muscle-invasive MPUC is characterized by high rates of progression to 
muscle-invasive and metastatic BC. A case series with 44 patients with non-muscle 
invasive MPUC, amongst those treated with BCG, 67% showed cancer progression 
with 22% developing metastatic disease, only 19% remained alive at the end of 
follow-up (10-yeat) without RC. Patients who underwent delayed RC after BCG 
treatment failure presented a median disease-specific survival (DSS) of 62% at 
10 years. On the other hand, patients treated with early RC had a 10-year median 
DSS of 72% [24].
Patients with UC with a micropapillary component doing upfront RC were not 
associated with worse recurrence-free, cancer specific or overall survival, when 
compared to those with pure UC [25].
Therefore, early RC has been considered the standard of care in most centers, 
however, there have been reports of reasonable outcomes in series in which bladder 
preservation therapies were applied in highly selected patients with a relatively 
small micropapillary component [26].
Although there is still scarce evidence regarding muscle-invasive MPUC and 
the role of Neo-adjuvant chemotherapy (NAC) in opposition to early RC, there 
have been reports showing no statistically significant differences in overall survival 
(OS) between the group who have undergone NAC plus RC vs. RC only [27]. A 
recent study analyzed the impact of adjuvant chemotherapy (AC) in the OS among 
patients with MPUC and the results demonstrated that, in contrast to pure UC, 
no survival benefit was observed in patients with this histology subtype [28]. 
Nevertheless, although these results could be explained by the more aggressive 
clinical behavior of this histologic variant, they can also be a consequence of small 
samples size, short follow-up periods and lack of risk stratification in most studies.
2.8 Lymphoepithelioma-like UC
Lymphoepithelioma-like UC (LLUC) resembles lymphoepithelioma of the 
nasopharynx and is characterized by a prominent lymphoid stroma (Figure 7) with 
T (predominantly CD3) and B lymphocytes, plasma cells, histiocytes, neutrophils 
and eosinophils. Major differential diagnosis comprises poorly differentiated UC 
with lymphoid inflammatory response or lymphoma [29, 30].
This histologic variant has been found to have a similar prognosis to conven-
tional UC as well as similar chemosensitivity and response to immunotherapy [31].
2.9 Plasmocytoid
Plasmacytoid UC is a rare histopathological variant of UC, comprising 1–3% of 
all UCs and is characterized by the presence of discohesive cells with eccentrically 
placed nuclei surrounded by abundant eosinophilic cytoplasm (Figure 8). This vari-
ant usually displays a diffusely infiltrative growth pattern, inducing minimal stromal 
reaction [32]. This morphology is not exclusive to UC, thus plasmacytoid UC (PUC) 
must be distinguished from melanoma and lymphoma. Immunohistochemical 
markers such as CK7, CK20 uroplakin II, and GATA-3 can be useful in the dif-
ferentiation in doubtful situations [33]. It is also characterized by a distinct growth 
pattern in which tumour cells can manifest distant from macroscopic disease with 
the absence of a desmoplastic reaction making it more challenging to determine the 
plane between the tumour and normal tissue. A wide margin of resection is therefore 
mandatory to ensure an adequate resection at the time of RC [32].
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Mutations in CDH1 are pathognomonic of PUC and result in the loss of 
E-cadherin expression in its tumour cells, this is thought to explain the higher rates 
of tumour cell migration observed [34, 35].
Plasmacytoid UC response to intravesical BCG has not been clearly defined yet 
but given the fact that these tumors display a strong predilection for recurrence, 
especially in peritoneal lining, even in cases when non-muscle invasiveness is 
encountered, early RC seems to provide a more effective control of the disease [36].
Figure 7. 
Characterized by syncytial sheets of tumor cells and a prominent chronic inflammatory infiltrate in the stroma. 
The infiltrate is composed largely of lymphocytes, plasma cells, eosinophils, and other inflammatory cells which 
may create an appearance of chronic cystitis or malignant lymphoma (HE × 100).
Figure 8. 
PUC usually displays single tumor cells with plasmacytoid features infiltrating loose myxoid stroma. It shows 
discohesive tumour cells with eccentrically located nuclei and abundant eosinophilic cytoplasm (HE × 200).
9
Bladder Cancer Variant Histologies: Epidemiology, Diagnosis, Treatment and Prognosis
DOI: http://dx.doi.org/10.5772/intechopen.98246
The role of NAC/AC is still unclear in PUC, although initial evidence sug-
gested this histologic variant was chemosensitive, more recent data suggests that 
platin based regimens confer no survival enhancement and that even in patients 
who achieve pT0 stage after cystectomy after RC, poor prognosis is maintained in 
PUC [36, 37].
2.10 Sarcomatoid
Sarcomatoid UC accounts for approximately 0.3% of all UCs. This histologic 
variant is characterized highly variable morphology exhibiting both epithelial and 
mesenchymal differentiation with high-grade spindle cells (Figure 9). Previous 
exposure to radiotherapy (RT) and intravesical cyclophosphamide are known risk 
factors [38].
Sarcomatoid differentiation has been associated with a very poor prognosis, 
since it usually presents at an advanced stage [38]. However recent series demon-
strated no differences in comparison with same stage pure UC, regarding disease-
specific, all-cause mortality and overall survival [28]. A survival benefit was not 
found in patients undergoing NAC or AC, suggesting this variant might be particu-
larly resistant to chemotherapy [39].
2.11 Clear cell
Clear cell UC is a very rare variant of UC characterized by tumour cells with 
glycogen-rich cytoplasm (Figure 10). It is crucial to do the correct differential 
diagnosis among clear cell UC, clear cell adenocarcinoma of the bladder, metastatic 
clear cell renal cell carcinoma or clear cell carcinoma of the female genital tract [28].
Only a few case reports are available for this rare histologic variant. The evi-
dence suggests a high progression rate to muscle-invasive and metastatic BC, and 
although treatment strategy is poorly defined, an aggressive approach with early 
RC is advocated [40].
Figure 9. 
It contains both carcinoma as well as sarcomatous areas usually with high-grade urothelial carcinoma on the 
surface and a high-grade undifferentiated sarcoma underneath in the lamina propria (HE × 100).
Modern Approach to Diagnosis and Treatment of Bladder Cancer
10
3. Non-Urothelial Variants
Non-urothelial BC can be categorized as epithelial and non-epithelial tumors. 
Approximately 90% are epithelial, including squamous cell carcinoma, adeno-
carcinoma and small-cell carcinoma. Non-epithelial tumors are rare, and include 
sarcoma, corinosarcoma, paraganglioma, melanoma and lymphoma [41]. In this 
section we will restrict our description to the most common subtypes.
4. Squamous Cell Carcinoma
Squamous Cell Carcinoma (SCC) represents the most common non-urothelial 
histologic variant, accounting for almost 2–5% of all BC in the western world and 
approximately 30% in endemic regions (Egypt and other parts of Africa) due to 
the parasite Schistosoma haematobium infection, which causes bilharzial SCC [42]. 
Non-bilharzial SCC is associated with chronic inflammation of the urothelium as a 
result of chronic urinary tract infection, long-term indwelling catheters and bladder 
calculi. In contrast to UC, the relationship between SCC and cigarette smoking in 
not clearly established [43].
In terms of histological characteristics, SCC contains keratin pearl inclusions 
and granules (Figure 11). Moreover, microscopic analysis shows that most SCC 
tumors are moderately to poorly differentiated tumors.
SCC tends to appear in the seventh decade of life, except for spinal cord injured 
patients which can present at younger ages and is characterized by a slight male pre-
dominance with a higher proportion of non-Caucasians [44]. SCC is associated with 
more advanced disease at presentation compared to UC, with 70% of cases showing 
muscle-invasiveness at time of diagnosis, with a higher propensity for nodal involve-
ment and metastatic disease [45]. Even in patients with T1 staging at diagnosis, pure 
SCC has been identified as an independent predictor of mortality in patients who 
did not undergo early cystectomy [46]. However, data from studies has also reported 
that, in cases in which the tumor was confined to the bladder wall and the bladder 
was surgically removed as part of the initial treatment, SCC histologic features were 
not associated with increased mortality when compared to UC [41, 47].
Figure 10. 
Clear cell variant of urothelial carcinoma consists of abundant clear cytoplasm due to glycogen content and it is 
characterized by large nests of tumour cells with high- grade nuclear atypia and clear cytoplasm (HE × 200).
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This histological subtype has been associated with poorer OS, even when 
adjusted for stage. However, bilharzial-associated SCC, which usually presents at 
a younger age, is associated with lower stages at diagnosis, and a more indolent 
disease course with subsequent better survival outcomes [48].
In opposition to UC, NAC has not demonstrated a statistically significant 
improvement in OS among patients with the SCC histology, treated with RC [49].
Regarding radiation therapy, there is some evidence that treatment with pre-
operative RT may improve disease-free survival comparing with RC alone [49]. 
Moreover, since SCC histology subtype is notoriously chemo-resistant to most 
regiments used for metastatic UC, radiotherapy can have an important therapeutic 
role [50]. This data was, however, obtained from retrospective studies with a very 
limited number of cases, suggesting that conclusions must be further evaluated.
Based on the best published evidence, early RC remains the mainstay therapy 
in patients with high-risk SCC, even when non-muscle invasive staging is observed 
[28]. It is important to note that, unlike other histologic subtypes, pelvic lymph 
node dissection (PLND) was associated with an improvement in OS [51].
5. Adenocarcinoma
Adenocarcinoma (AC) of the bladder can be primary or secondary [if it results 
from a contiguous invasion from other organs such as prostate, colon or uterus 
(endometrium and cervix), or metastatic spread (lung)]. Primary AC accounts 
for roughly 2% of all BCs and is divided into two subtypes: Urachal (10%) and 
nonurachal AC. There are also different types of adenocarcinomas that have been 
described, including glandular (Figure 12), colloid, papillary, signet ring and clear 
cell. Known risk factors include bilharziasis, chronic inflammation and bladder 
exstrophy (even in patients who have undergone correction in the neonatal period) 
[43, 51]. The diagnosis of primary AC of the bladder should only be made if second-
ary involvement from other organs is excluded. This entity has been shown to be 
more common in females, with a higher proportion among non-caucasians [52].
Figure 11. 
The image shows presence of keratin pearls and copious keratin production, unequivocal for squamous 
differentiation (HE × 100).
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Bladder AC usually presents at an advanced stage, with muscle-invasive or 
metastatic disease. For localized disease, RC is currently the treatment of choice. 
However, when matched for stage, primary AC appears to have similar outcomes to 
UC [53]. In patients with NMIBC disease, a SEER analysis reports that, in non-ura-
chal AC, transurethral resection (TUR) alone increased mortality risk, compared 
with early cystectomy [54]. There is currently no evidence available regarding the 
effect of immuno- or chemotherapy.
Urachal AC seems to present more favorable prognosis compared with non-
urachal AC. Partial cystectomy (with en bloc resection of the bladder dome and 
umbilical ligament) is an alternative option to RC, in selected patients [55, 56]. 
Although urachal AC also seems more likely to present as metastatic disease in 
comparison to UC, the previous mentioned better prognosis is most probably partly 
due to be diagnosed among younger patients, with less co-morbidities [28].
Current data about NAC or AC in adenocarcinoma patients, although very 
scarce, suggests that neither therapy confers an improvement in survival [57].
5.1 Small Cell Carcinoma
The urinary bladder is the most common site for genitourinary extra-pulmonary 
neuroendocrine/small cell carcinomas. Small cell carcinoma (SmCC) accounts for 
less than 1% of BCs. It is a neuroendocrine tumour characterized by nests or solid 
sheets of small cells with enlarged nuclei, evenly dispersed chromatin with a “salt 
and pepper” pattern (Figure 13), with abundant resemblance to its pulmonary 
counterpart. It often co-exists with conventional UC, SCC and AC. Neuroendocrine 
markers such as chromogranin, synaptophysin and CD56 are expressed in SmCC 
[43]. Mean age presentation sits in the seventh-decade of life, with a strong male 
predominance (5:1) [55]. SmCC also shows similar characteristics to small cell 
carcinomas of the lung including ectopic hormone production, which can lead to 
clinically relevant hyperkalemia and hypophosphatemia [56, 58].
Figure 12. 
Intestinal-type adenocarcinoma shows malignant colonic glands with high-grade columnar cells and necrosis in 
the lumens (HE × 40).
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This histologic variant is also characterized by its aggressiveness, exhibiting 
rapid growth with a predilection for early metastases, and a particularly high 
propensity for brain metastasis [59].
Contrarily to many of other histologic variants, a treatment strategy based on 
NAC followed by RC or RT represents the optimal strategy, based on several studies 
that demonstrated the chemosensitivity (with platinum-based therapy) of SmCC 
with an improvement in survival [59].
In terms of prognosis, SmCC presents a similar outcome to pure UC at same 
stages, except in the setting of diffuse metastatic disease in which it presents worse 
outcomes [60].
6. Conclusions
Bladder cancer with UC variants and non-urothelial subtypes have been clas-
sically described as tumors with a worse prognosis in comparison with pure UCs. 
However, the latter is mostly explained by a higher stage at the diagnosis among 
non-pure UC, since data from case-series and retrospective studies seems to suggest 
that, among the majority of variants, the prognosis is similar to pure UC, after 
adjustment for the disease stage.
Current diagnosis of variant histology in BC provides clinically relevant infor-
mation to the physician and a novel framework to stratify patients according to 
prognosis, risk of recurrence and expected response to a given therapy. However, 
the management of this conditions remains challenging. Currently, RC preceded, 
in some tumors by NAC, constitutes the recommended treatment approach for 
resecable disease; AC is most commonly unsuccessful and data on immunotherapy 
is still scant. Regarding immunotherapy, it appears that drugs active in the PD-1 
pathway are independent of histology [60].
Additionally, molecular alterations unique to these variants could be of use, in 
the future, as targeted therapies could emerge as a treatment option. However, fur-
ther investigation is still needed to understand more clearly the diagnostic criteria 
Figure 13. 
Small cells with artifacts that make it difficult to distinguish between cytoplasm and nucleus (HE × 100).
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determine optimal therapy regimens.
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